Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cathay BiotechSHSE:688065 -0.02%92 Days Payable is 224.37 as of Mar. 2026, which is 9% below its 10-year median of 245.36. GuruFocus rates SHSE:688065 with a GF Score™ of 92/100 and a GF Value™ of ¥50.12 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,554 Chemicals companies, Cathay Biotech ranks better than 95.37% on this metric.
The historical rank and industry rank for Cathay Biotech's Days Payable or its related term are showing as below:
SHSE:688065'
s Days Payable Range Over the Past 10 Years
Min: 78.63 Med: 245.36 Max: 332.41
Current: 226.58
During the past 10 years, Cathay Biotech's highest Days Payable was 332.41. The lowest was 78.63. And the median was 245.36.
SHSE:688065's Days Payable is ranked better than 95.37% of 1554
companies
in the Chemicals industry
Industry Median: 59.565
vs SHSE:688065: 226.58
Cathay Biotech's Days Payable
declined
from Mar. 2025 (249.03) to Mar. 2026 (224.37).
It may suggest that Cathay Biotechaccelerated paying its suppliers.
Cathay Biotech Days Payable Related Terms
Cathay Biotech Days Payable Historical Data
* Premium members only.
The historical data trend for Cathay Biotech's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Chemicals subindustry, Cathay Biotech's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cathay Biotech Days Payable vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Cathay Biotech's Days Payable distribution charts can be found below:
* The bar in red indicates where Cathay Biotech's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cathay Biotech's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cathay Biotech (SHSE:688065) has a Days Payable of 224.37 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cathay Biotech and its competitors. This is near median its historical median of 245.36. Over the past decade, Cathay Biotech's Days Payable has ranged from 78.63 to 332.41. According to the industry distribution chart, Cathay Biotech ranks #72 out of 1554 companies in the Chemicals industry, placing it in the top 4.6%.
Is Cathay Biotech's Days Payable too high?
Cathay Biotech's current Days Payable of 224.37 is near median its 10-year median of 245.36. Over the past 10 years, this metric has ranged from a low of 78.63 to a high of 332.41. The Chemicals industry median Days Payable is 59.57. Cathay Biotech's value of 224.37 is 276.7% above this industry median. Based on the distribution chart, Cathay Biotech ranks #72 out of 1554 companies in the Chemicals industry, which is in the top quartile — a strong position relative to peers. Overall, Cathay Biotech has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cathay Biotech's Days Payable compare to DOW?
According to the Chemicals industry distribution chart, Cathay Biotech ranks #72 out of 1554 companies for Days Payable. This places Cathay Biotech in the top 5% of its industry — outperforming the majority of peers. The industry median Days Payable is 59.57. Cathay Biotech's value of 224.37 is 276.7% above this benchmark. Historically, Cathay Biotech's own Days Payable has ranged from 78.63 to 332.41 over the past decade. While the company's 10-year median is 245.36 vs. the industry median of 59.57, Cathay Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Chemicals company?
The median Days Payable among Chemicals companies is 59.57, based on 1,554 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cathay Biotech's current Days Payable of 224.37 is 276.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cathay Biotech and its competitors. For the Chemicals industry, the median Days Payable is 59.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cathay Biotech's current Days Payable is 224.37, which is near median its own 10-year median of 245.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cathay Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cathay Biotech (SHSE:688065) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥50.12, compared to a current price of ¥42.75 — trading 14.7% below its estimated fair value. The current Days Payable is 224.37, which is near median its 10-year median of 245.36 and 276.7% above the Chemicals industry median of 59.57. Cathay Biotech's overall GF Score™ is 92/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cathay Biotech (SHSE:688065), the current Days Payable is 224.37 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cathay Biotech (SHSE:688065) Overvalued in 2026?
Based on GuruFocus' analysis, Cathay Biotech stock appears to be undervalued.
The current stock price of ¥42.75 is trading 14.7% below its estimated GF Value™ of ¥50.12.
GuruFocus considers Cathay Biotech to be Modestly Undervalued.
Key valuation signals for SHSE:688065:
Days Payable: 224.37 (near median its 10-year median of 245.36)
GF Value™: ¥50.12 vs. price of ¥42.75 (14.7% below fair value)
Industry Position: 276.7% above the Chemicals median (#72 of 1554)
No single metric tells the full story. See the SHSE:688065 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cathay Biotech Inc is engaged in research, development, production, and sales of new bio-based materials. The company owns the TERRYL brand, which focuses on bio-based polyamide fibers for textiles, and ECOPENT, which serves the engineering materials market.
92GF Score
Get the complete analysis for SHSE:688065
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688065 has been successfully added to your 
